Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities

被引:100
|
作者
Venhorst, J
ter Laak, AM
Commandeur, JNM
Funae, Y
Hiroi, T
Vermeulen, NPE
机构
[1] Vrije Univ Amsterdam, Dept Pharmacochem, Fac Sci, Div Mol Toxicol,Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands
[2] Osaka City Univ, Sch Med, Chem Lab, Abeno Ku, Osaka 545, Japan
关键词
D O I
10.1021/jm0209578
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ligand-binding characteristics of rat and human CYP2D isoforms, i.e., rat CYP2D1-4 and human CYP2D6, were investigated by measuring IC50 values of 11 known CYP2D6 ligands using 7-methoxy-4-(aminomethyl)coumarin (MAMC) as substrate. Like CYP2D6, all rat CYP2D isozymes catalyzed the O-demethylation of MAMC with K-m and V-max values ranging between 78 and 145 muM and 0.048 and 1.122 min(-1), respectively. To rationalize observed differences in the experimentally determined IC50 values, homology models of the CYP2D isoforms were constructed. A homology model of CYP2D6 was generated on the basis of crystallized rabbit CYP2C5 and was validated on its ability to reproduce binding orientations corresponding to metabolic profiles of the substrates and to remain stable during unrestrained molecular dynamics simulations at 300 K Twenty-two active site residues, sharing up to 59% sequence identity, were identified in the CYP2D binding pockets and included CYP2D6 residues Phe120, Glu216, and Asp301. Electrostatic potential calculations displayed large differences in the negative charge of the CYP2D active sites, which was consistent with observed differences in absolute IC50 values. MD studies on the binding mode of sparteine, quinidine, and quinine in CYP2D2 and CYP2D6 furthermore concurred well with experimentally determined IC50 values and metabolic profiles. The current study thus provides new insights into differences in the active site topology of the investigated CYP2D isoforms.
引用
收藏
页码:74 / 86
页数:13
相关论文
共 50 条
  • [31] Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
    Hai-yan XU~2 Zhi-yong XIE~2 Peng ZHANG~2 Jin SUN~3 Feng-ming CHU~4 Zong-ru GUO~4 Da-fang ZHONG~(2
    ~3Department of Biopharmaceutics
    ~4Institute of Materia Medica
    Acta Pharmacologica Sinica, 2006, (03) : 372 - 380
  • [32] Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
    Xu, HY
    Xie, ZY
    Zhang, P
    Sun, J
    Chu, FM
    Guo, ZR
    Zhong, DF
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (03) : 372 - 380
  • [33] Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
    Hai-yan Xu
    Zhi-yong Xie
    Peng Zhang
    Jin Sun
    Feng-ming Chu
    Zong-ru Guo
    Da-fang Zhong
    Acta Pharmacologica Sinica, 2006, 27 : 372 - 380
  • [34] The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia
    Danek, Przemyslaw J.
    Daniel, Wladyslawa A.
    CELLS, 2022, 11 (21)
  • [35] Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking
    Li, Weihua
    Tang, Yun
    Liu, Hong
    Cheng, Jiagao
    Zhu, Weiliang
    Jiang, Hualiang
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 71 (02) : 938 - 949
  • [36] Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19
    Hichiya, H
    Kuramoto, S
    Yamamoto, S
    Shinoda, S
    Hanioka, N
    Narimatsu, S
    Asaoka, K
    Miyata, A
    Iwata, S
    Nomoto, M
    Satoh, T
    Kiryu, K
    Ueda, N
    Naito, S
    Tucker, GT
    Ellis, SW
    BIOCHEMICAL PHARMACOLOGY, 2004, 68 (01) : 165 - 175
  • [37] Optimizing QSAR Models for Predicting Ligand Binding to the Drug-Metabolizing Cytochrome P450 Isoenzyme CYP2D6
    Saraceno, Marilena
    Massarelli, Ilaria
    Imbriani, Marcello
    James, Thomas L.
    Bianucci, Anna M.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2011, 78 (02) : 236 - 251
  • [38] Differential Cytochrome P450 2D Metabolism Alters Tafenoquine Pharmacokinetics
    Vuong, Chau
    Xie, Lisa H.
    Potter, Brittney M. J.
    Zhang, Jing
    Zhang, Ping
    Duan, Dehui
    Nolan, Christina K.
    Sciotti, Richard J.
    Zottig, Victor E.
    Nanayakkara, N. P. Dhammika
    Tekwani, Babu L.
    Walker, Larry A.
    Smith, Philip L.
    Paris, Robert M.
    Read, Lisa T.
    Li, Qigui
    Pybus, Brandon S.
    Sousa, Jason C.
    Reichard, Gregory A.
    Smith, Bryan
    Marcsisin, Sean R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) : 3864 - 3869
  • [39] The Effect of the Selective N-methyl-D-aspartate (NMDA) Receptor GluN2B Subunit Antagonist CP-101,606 on Cytochrome P450 2D (CYP2D) Expression and Activity in the Rat Liver and Brain
    Haduch, Anna
    Bromek, Ewa
    Puklo, Renata
    Jastrzebska, Joanna
    Danek, Przemyslaw Jan
    Daniel, Wladyslawa Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [40] Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D
    Delaforge, M
    Jaouen, M
    Bouille, G
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 1999, 7 (03) : 153 - 158